Summary
                        
        
                            Drug failure and high development cost (est. €2.3bn/new drug) has driven enormous growth in market need for scientific tests and models of disease that better translate from the bench (in vitro) to the bedside (in vivo). Critical tests to facilitate this are either not...
                    
    
        
                                 
                    More information & hyperlinks
                        
        | Web resources: | http://www.agilent.com/en/metatox-hs | 
 
                             
                             
                            